59
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Non-alcoholic fatty liver disease (NAFLD) is a common condition that progresses in some patients to steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). Here we used healthcare records of 18 million adults to estimate risk of acquiring advanced liver disease diagnoses in patients with NAFLD or NASH compared to individually matched controls.

          Methods

          Data were extracted from four European primary care databases representing the UK, Netherlands, Italy and Spain. Patients with a recorded diagnosis of NAFLD or NASH (NAFLD/NASH) were followed up for incident cirrhosis and HCC diagnoses. Each coded NAFLD/NASH patient was matched to up to 100 “non-NAFLD” patients by practice site, gender, age ± 5 years and visit recorded within ± 6 months. Hazard ratios (HR) were estimated using Cox models adjusted for age and smoking status and pooled across databases by random effects meta-analyses.

          Results

          Out of 18,782,281 adults, we identified 136,703 patients with coded NAFLD/NASH. Coded NAFLD/NASH patients were more likely to have diabetes, hypertension and obesity than matched controls. HR for cirrhosis in patients compared to controls was 4.73 (95% CI 2.43–9.19) and for HCC, 3.51 (95% CI 1.72–7.16). HR for either outcome was higher in patients with NASH and those with high-risk Fib-4 scores. The strongest independent predictor of a diagnosis of HCC or cirrhosis was baseline diagnosis of diabetes.

          Conclusions

          Real-world population data show that recorded diagnosis of NAFLD/NASH increases risk of life-threatening liver outcomes. Diabetes is an independent predictor of advanced liver disease diagnosis, emphasising the need to identify specific groups of patients at highest risk.

          Electronic supplementary material

          The online version of this article (10.1186/s12916-019-1321-x) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.

          Hepatocellular carcinoma (HCC) can develop in individuals without cirrhosis. We investigated risk factors for development of HCC in the absence of cirrhosis in a U.S.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.

            The degree of generalisability of patient databases to the general population is important for interpreting database research. This report describes the representativeness of The Health Improvement Network (THIN), a UK primary care database, of the UK population. Demographics, deprivation (Townsend), Quality and Outcomes Framework (QOF) condition prevalence and deaths from THIN were compared with national statistical and QOF 2006/2007 data. Demographics were similar although THIN contained fewer people aged under 25 years. Condition prevalence was comparable, e.g. 3.5% diabetes prevalence in THIN, 3.7% nationally. More THIN patients lived in the most affluent areas (23.5% in THIN, 20% nationally). Between 1990 and 2009, standardised mortality ratio ranged from 0.81 (95% CI: 0.39-1.49; 1990) to 0.93 (95% CI: 0.48-1.64; 1995). Adjusting for demographics/deprivation, the 2006 THIN death rate was 9.08/1000 population close to the national death rate of 9.4/1000 population. THIN is generalisable to the UK for demographics, major condition prevalence and death rates adjusted for demographics and deprivation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The strength of primary care in Europe: an international comparative study.

              A suitable definition of primary care to capture the variety of prevailing international organisation and service-delivery models is lacking. Evaluation of strength of primary care in Europe. International comparative cross-sectional study performed in 2009-2010, involving 27 EU member states, plus Iceland, Norway, Switzerland, and Turkey. Outcome measures covered three dimensions of primary care structure: primary care governance, economic conditions of primary care, and primary care workforce development; and four dimensions of primary care service-delivery process: accessibility, comprehensiveness, continuity, and coordination of primary care. The primary care dimensions were operationalised by a total of 77 indicators for which data were collected in 31 countries. Data sources included national and international literature, governmental publications, statistical databases, and experts' consultations. Countries with relatively strong primary care are Belgium, Denmark, Estonia, Finland, Lithuania, the Netherlands, Portugal, Slovenia, Spain, and the UK. Countries either have many primary care policies and regulations in place, combined with good financial coverage and resources, and adequate primary care workforce conditions, or have consistently only few of these primary care structures in place. There is no correlation between the access, continuity, coordination, and comprehensiveness of primary care of countries. Variation is shown in the strength of primary care across Europe, indicating a discrepancy in the responsibility given to primary care in national and international policy initiatives and the needed investments in primary care to solve, for example, future shortages of workforce. Countries are consistent in their primary care focus on all important structure dimensions. Countries need to improve their primary care information infrastructure to facilitate primary care performance management.
                Bookmark

                Author and article information

                Contributors
                44 20 7882 2308 , w.alazawi@qmul.ac.uk
                Journal
                BMC Med
                BMC Med
                BMC Medicine
                BioMed Central (London )
                1741-7015
                20 May 2019
                20 May 2019
                2019
                : 17
                : 95
                Affiliations
                [1 ]ISNI 0000 0001 2162 0389, GRID grid.418236.a, Real World Data, GlaxoSmithKline, ; Uxbridge, UK
                [2 ]ISNI 0000 0000 8800 7493, GRID grid.410513.2, Worldwide Research and Development, Pfizer, Genome Sciences and Technologies, ; New York, USA
                [3 ]ISNI 000000040459992X, GRID grid.5645.2, Erasmus Universitair Medisch Centrum, ; Rotterdam, Netherlands
                [4 ]Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina, Barcelona, Spain
                [5 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Centre for Statistics in Medicine, NDORMS, , University of Oxford, ; Oxford, UK
                [6 ]Quintile IMS, London, UK
                [7 ]Health Search, Italian College of General Practitioners and Primary Care, Firenze, Italy
                [8 ]ISNI 0000 0004 0393 4335, GRID grid.418019.5, Genetics, GlaxoSmithKline, ; Collegeville, PA USA
                [9 ]ISNI 0000 0001 2162 0389, GRID grid.418236.a, GlaxoSmithKline, Medicines Research Centre, ; Cambridge, UK
                [10 ]ISNI 0000 0001 2193 314X, GRID grid.8756.c, University of Glasgow, ; Glasgow, UK
                [11 ]ISNI 0000 0001 2161 2573, GRID grid.4464.2, Barts Liver Centre, Blizard Institute, Queen Mary, , University of London, ; London, UK
                Author information
                http://orcid.org/0000-0002-3891-5914
                Article
                1321
                10.1186/s12916-019-1321-x
                6526616
                31104631
                4bb2e3e4-850e-4c36-9dc9-55efb25ee868
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 17 January 2019
                : 10 April 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100010767, Innovative Medicines Initiative;
                Award ID: 115372
                Funded by: FundRef http://dx.doi.org/10.13039/501100000265, Medical Research Council;
                Award ID: MR/N00308X/1
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2019

                Medicine
                cirrhosis,hepatocellular cancer,nafld,nash,population
                Medicine
                cirrhosis, hepatocellular cancer, nafld, nash, population

                Comments

                Comment on this article